Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Carcinoma, Hepatocellular 2Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1Digestive System Diseases 1Carcinoma 1Advanced Pancreatic Cancer 1

Interventions

Irinotecan 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Oxaliplatin 4Fluorouracil 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Leucovorin 3pembrolizumab 2Sorafenib 2Paclitaxel 2Nivolumab 2Drug Therapy 2Cyclophosphamide 2Colonoscopy 2Cetuximab 2Aspirin 2Ascorbic Acid 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1penpulimab 1lutetium Lu 177 dotatate 1linifanib 1halofantrine 1guadecitabine 1golotimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Diseases × penpulimab × Gastrointestinal × Clear all
NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡